List view / Grid view
19 November 2014 | By BerGenBio
BerGenBio AS, an oncology biopharmaceutical company, announces that the US Food and Drug Administration (FDA) has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML)...
19 November 2014 | By Nosopharm
These high-profile experts will help with the quick and safe launch of the preclinical development program for a new class of antibiotics...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
13 November 2014 | By Amgen
Thirteen presentations include new analyses of PCSK9 inhibitor at upcoming American Heart Association Scientific sessions...
12 November 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration with the National Cancer Centre Singapore (NCCS)...
12 November 2014 | By Enterome
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases...
11 November 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced that it has selected research partners for its 2014 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project...
7 November 2014 | By Felicitex Therapeutics and Selvita
Felicitex Therapeutics and Selvita have announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors...
7 November 2014 | By CARLINA Technologies
CARLINA Technologies announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein...
6 November 2014 | By Cardio3 BioSciences
Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery...
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
28 October 2014 | By TxCell
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease...
24 October 2014 | By The Institute of Cancer Research, London
Leading expert calls for major changes to restock pipeline with innovative cancer treatments...
22 October 2014 | By The European Infrastructure for Translational Medicine
EATRIS, TIA, NCATS and CDRD join forces to share knowledge and insight..
22 October 2014 | By Rosetta Genomics Ltd
Rosetta Genomics Ltd. announces the initiation by the European Infrastructure for Translational Medicine, of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic...
